Reply to Trosch et al. Comment on “Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442”
Open Access
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing InformationToxins, 2024
- Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type ADrugs, 2021
- DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)Plastic and Reconstructive Surgery, 2020
- AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in PatientsToxins, 2018
- Comparison of botulinum neurotoxin type A formulations in AsiaClinical, Cosmetic and Investigational Dermatology, 2018
- A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystoniaJournal of Neurology, 2016
- A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystoniaJournal of Neural Transmission, 2013
- Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaJournal of the Neurological Sciences, 2011
- Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs in R&D, 2010
- Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled studyMovement Disorders, 2005